Improved insulin sensitivity by anti-TNF antibody treatment in patients with rheumatic diseases
| Autor: | Frank C. Huvers, Calin D. Popa, M.G. Netea, Frank H J van den Hoogen, Cees J. Tack |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Adult
Male medicine.medical_specialty medicine.medical_treatment Immunology Adipokine Type 2 diabetes General Biochemistry Genetics and Molecular Biology Insulin resistance Rheumatology Rheumatic Diseases Internal medicine medicine Humans Immunology and Allergy Prospective Studies Letters Interleukin 6 Aged biology Tumor Necrosis Factor-alpha business.industry Insulin Leptin Antibodies Monoclonal Middle Aged Glucose clamp technique medicine.disease Infliximab Endocrinology Antirheumatic Agents Glucose Clamp Technique biology.protein Female Insulin Resistance Metabolic syndrome business |
| Zdroj: | Annals of the Rheumatic Diseases. 66:558-559 |
| ISSN: | 0003-4967 |
| DOI: | 10.1136/ard.2006.062323 |
| Popis: | Insulin resistance is a key factor in the pathogenesis of the metabolic syndrome and type 2 diabetes, but the underlying mechanisms remain poorly understood. Adipocytokines, including tumour necrosis factor α (TNFα), interleukin 6, leptin and adiponectin,1,2 are increasingly recognised as important regulators of both insulin sensitivity, as well as inflammation, and a dysregulation of their levels and/or functions has been shown in both obesity and rheumatoid arthritis.3 Further investigations have substantiated the important negative effects of TNFα on insulin-mediated glucose uptake and the development of insulin resistance.4 In this study, the influence of therapeutic TNFα blockade on insulin sensitivity was investigated in regularly treated patients with rheumatic diseases. A group of eight patients who were non-diabetic and having various chronic inflammatory disorders (table 1) were investigated in an open prospective … |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|